A federal judge has finalized an agreement by Pfizer to pay $325 million to settle claims it marketed off-label uses of its epilepsy drug Neurontin.

The decision ends a decade-old class-action lawsuit alleging Pfizer unit Warner-Lambert promoted Neurontin (gabapentin) for treatment of migraine headaches, depression and as a painkiller. None of those uses was approved by the FDA.

Pfizer revealed the proposed settlement in June, and didn’t admit any wrongdoing. The settlement to third-party pharmaceutical payers, including insurance companies and union health plans, was approved by Judge Patti Saris in the U.S. District Court for the District of Massachusetts. — Robert King

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.